(19)
(11)EP 3 429 572 B1

(12)EUROPEAN PATENT SPECIFICATION

(45)Mention of the grant of the patent:
05.05.2021 Bulletin 2021/18

(21)Application number: 17710897.4

(22)Date of filing:  14.03.2017
(51)International Patent Classification (IPC): 
A61K 31/121(2006.01)
A61K 31/4188(2006.01)
A61K 9/00(2006.01)
A61K 31/4745(2006.01)
A61K 47/00(2006.01)
A61P 35/00(2006.01)
(86)International application number:
PCT/EP2017/056022
(87)International publication number:
WO 2017/157955 (21.09.2017 Gazette  2017/38)

(54)

COMBINATION THERAPY FOR PROLIFERATIVE DISEASES

KOMBINATIONSTHERAPIE FÜR PROLIFERATIVE ERKRANKUNGEN

POLYTHÉRAPIE POUR LES MALADIES PROLIFÉRATIVES


(84)Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)Priority: 14.03.2016 GB 201604316

(43)Date of publication of application:
23.01.2019 Bulletin 2019/04

(73)Proprietor: Avexxin AS
7052 Trondheim (NO)

(72)Inventors:
  • JOHANSEN, Berit
    7052 Trondheim (NO)
  • FEUERHERM, Astrid Jullumstrø
    7052 Trondheim (NO)

(74)Representative: Dehns 
St. Bride's House 10 Salisbury Square
London EC4Y 8JD
London EC4Y 8JD (GB)


(56)References cited: : 
EP-B1- 1 888 578
WO-A1-2015/181135
  
  • MAIRA SAUVEUR-MICHEL ET AL: "Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity", MOLECULAR CANCER THERAPEUTICS, vol. 7, no. 7, 8 February 2012 (2012-02-08), pages 1851-1863, XP002668980, DOI: 10.1158/1535-7163.MCT-08-0017
  • EDWARDS IRIS J ET AL: "Omega-3 Fatty Acids and PPARgamma in Cancer.", PPAR RESEARCH, vol. 2008, 358052, 2008, pages 1-14, XP002769731, ISSN: 1687-4757
  • ANDREA HUWILER ET AL: "The [omega]3-polyunsaturated fatty acid derivatives AVX001 and AVX002 directly inhibit cytosolic phospholipase A 2 and suppress PGE 2 formation in mesangial cells", BRITISH JOURNAL OF PHARMACOLOGY, vol. 167, no. 8, 29 December 2012 (2012-12-29), pages 1691-1701, XP055116796, ISSN: 0007-1188, DOI: 10.1111/j.1476-5381.2012.02114.x
  • GAUTAM PRSON ET AL: "Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells.", MOLECULAR CANCER, vol. 15, no. 1, 34, 10 May 2016 (2016-05-10), pages 1-16, XP002769732, ISSN: 1476-4598
  
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).


Description


[0001] This disclosure relates to a pharmaceutical composition or combination product comprising certain polyunsaturated long-chain ketones in combination with certain protein kinase inhibitors, in particular phosphatidylinositol-4,5-bisphosphate 3-kinase inhibitors (PI3K) and more particularly dual inhibitors of PI3K and mammalian target of rapamycin (mTOR). The disclosure also relates to the use of said pharmaceutical composition or combination product for the treatment or prevention of proliferative conditions such as cancer, e.g. breast cancer. The disclosure also relates to methods of treating or preventing proliferative conditions in patients comprising administration of the pharmaceutical composition or combination product of the invention to the patient.

Background



[0002] Basal-like breast cancer (BLBC), which represents -15 % of all breast cancers, is an aggressive molecular subtype of the disease associated with poor prognosis. Most BLBCs are triple-negative (lacking expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2) and thus unresponsive to currently available targeted therapies. Hence, new molecular targets for treatment are called for.

[0003] The present inventors have devised a new combination therapy that targets proliferative conditions in general and breast cancer in particular.

[0004] The invention relies on the combination of a long chain polyunsaturated ketone compound and a specific dual inhibitor of PI3K and mTOR. The present inventors have surprisingly found that the combination of these two compounds leads to a combination therapy that works synergistically. In particular, the combination has been shown to synergistically reduce breast cancer cell viability.

Summary of Invention



[0005] Thus, viewed from one aspect the invention provides a pharmaceutical composition, combination product or kit comprising:
  1. (A) a compound of forumla (I)

    X= CF3 = Compound A or

    X= CF3 = Compound B or a salt thereof; and
  2. (B) a compound of fomula (X)

    or a salt thereof.


[0006] Viewed from another aspect the invention provides a pharmaceutical composition for simultaneous, sequential or separate use comprising a kit comprising a first composition comprising a compound (I)

X= CF3 = Compound A or

X= CF3 = Compound B or a salt thereof; and a pharmaceutically-acceptable diluent or carrier; and
a second composition comprising a compound (X)

or a pharmaceutically acceptable salt thereof and a pharmaceutically-acceptable diluent or carrier.

[0007] Viewed from another aspect the invention provides a pharmaceutical composition or combination product as hereinbefore defined for use in the treatment or prevention of a proliferative disorder such as cancer, especially breast carcinoma.

Definitions



[0008] The invention relates both to a pharmaceutical composition in which compounds (I) and (X) are blended together in a single composition and to a combination product such as a kit in which the active compounds are provided in separate compositions but are designed for administration simultaneously, separately or sequentially.

[0009] A "combination" according to the invention refers to either a fixed combination in one dosage unit form, or a kit of parts for the combined administration where a compound of the formula (I) and its combination partner formula (X) (also referred to as "combination partner" or "therapeutic agent") may be administered independently at the same time or separately within time intervals, especially where these time intervals allow that the combination partners show a cooperative and preferably a synergistic effect.

[0010] A "combination product" as used herein means a product suitable for pharmaceutical use that results from the mixing or combining of more than one active ingredient and includes both fixed and non-fixed combinations of the active ingredients. The term "fixed combination" or "fixed dose" means that the active ingredients, e.g. a compound of formula (I) and its combination partner formula (X), are both administered to a patient simultaneously in the form of a single entity or dosage. The term "non-fixed combination" means that the active ingredients, e.g. a compound of formula (I) and the combination partner formula (X) are both administered to a patient as separate entities either simultaneously, concurrently or sequentially with no specific time limits, wherein such administration provides therapeutically effective levels of the two compounds in the body of the warm-blooded animal in need thereof.

[0011] All discussion below relating to preferred compounds of the invention is equally applicable to both these aspects of the invention.

Detailed Description



[0012] This invention concerns a combination therapy of a compound of formula (I) and a compound of formula (X). We have surprisingly found that this combination therapy results in synergy. Our results demonstrate a reduction in the viability of breast cancer cells, the composition or combination product offering a larger reduction than could have been expected from the use of individual compounds individually, i.e. the combination of the compounds produces an overall effect that is greater than the sum of the individual elements.

Proliferative Disorder



[0013] This invention relates to a new combination therapy for proliferative disorders. Preferably, the composition of the invention is used for the treatment of a proliferative disease selected from a benign or malignant tumor, carcinoma of the brain, kidney, liver, adrenal gland, bladder, breast, stomach, gastric tumors, ovaries, colon, rectum, prostate, pancreas, lung, vagina or thyroid, sarcoma, glioblastomas, multiple myeloma or gastrointestinal cancer.

[0014] It is especially preferred if the proliferative disorder is a mammary carcinoma. The composition or combination product of the invention can target specifically metatstaic breast adenocarcinoma.

Composition or combination product of the invention



[0015] The invention relies on the therapeutic combination of a compound of formula (I) and a compound of formula (X). The compound of formula (I) is

X= CF3 = Compound A or

X= CF3 = Compound B

[0016] The second component of the composition or product of the invention is a compound of formula (X)

or a salt thereof such as toluene sulphonic acid salt thereof. This compound is called BEZ235.

[0017] Alternatively, another combination product of the invention is BEZ235, Compound A and Compound B.

[0018] Where possible, the compounds of the invention can be administered in salt, hydrate or solvate form, especially salt form.

[0019] Typically, a pharmaceutical acceptable salt may be readily prepared by using a desired acid. The salt may precipitate from solution and be collected by filtration or may be recovered by evaporation of the solvent. For example, an aqueous solution of an acid such as hydrochloric acid may be added to an aqueous suspension of a compound of formula (X) and the resulting mixture evaporated to dryness (lyophilised) to obtain the acid addition salt as a solid. Alternatively, a compound of formula (X) may be dissolved in a suitable solvent, for example an alcohol such as isopropanol, and the acid may be added in the same solvent or another suitable solvent. The resulting acid addition salt may then be precipitated directly, or by addition of a less polar solvent such as diisopropyl ether or hexane, and isolated by filtration.

[0020] Suitable addition salts are formed from inorganic or organic acids which form non-toxic salts and examples are hydrochloride, hydrobromide, hydroiodide, sulphate, bisulphate, nitrate, phosphate, hydrogen phosphate, acetate, trifluoroacetate, maleate, malate, fumarate, lactate, tartrate, citrate, formate, gluconate, succinate, pyruvate, oxalate, oxaloacetate, trifluoroacetate, saccharate, benzoate, alkyl or aryl sulphonates (e.g. methanesulphonate, ethanesulphonate, benzenesulphonate or p-toluenesulphonate) and isethionate. Representative examples include trifluoroacetate and formate salts, for example the bis or tris trifluoroacetate salts and the mono or diformate salts, in particular the tris or bis trifluoroacetate salt and the monoformate salt.

[0021] Compounds of formula (I) may be manufactured using known chemical synthetic routes. It is convenient to begin synthesis from the commercially available compounds arachidonic acid (AA), EPA (all-Z-eicosa-5,8,11,14,17-pentaenoic acid) or DHA (all-Z-docosa-4,7,10,13,16,19-hexaenoic acid). Conversion of the acid functionality of these compounds into, for example a -COCF3 group can be achieved readily, e.g. by converting the carboxylic acid into its corresponding acid chloride and reacting the same with trifluoroacetic anhydride in the presence of pyridine.

[0022] Introduction of a heteroatom into the carbon chain is also achieved readily. Conveniently, for example, the starting acid is reduced to an alcohol and, if required, converted to the corresponding thiol. The nucleophilic thiol may then be reacted with a group such as BrCH2COCF3 thereby introducing the carbonyl and electron withdrawing species. Complete synthetic protocols may be found in J. Chem. Soc., Perkin Trans 1, 2000, 2271-2276 or J. Immunol., 1998, 161, 3421.

[0023] Synthesis methods for the preparation of compounds of formula (X) are described in EP-A-1888578, for example. Additional methods for assaying the activity of PI3K inhibitors, mTOR inhibitors and dual PI3K/mTOR inhibitors have been described. See WO2015/04939 and US Pat. Publication 2014/0066474, and Brana et al. (2012) BMC Med. 10:161, for example. The weight ratio of the compounds of formula (I) to compounds of formula (X) in composition or combination product of the invention will be guided by intended use, the age and general health of the subject, and other parameters known to those of skill. For example, a particular weight ratio suitable for certain applications may be 10 to 90 wt% to 90 to 10 wt%, such as 30 to 70 wt% to 70 to 30 wt%.

[0024] More preferably, the amounts of each compound are determined in molar terms, and the ratio of each is 5:1 to 1:5 moles, such as 2:1 to 1:2 moles. Often, the compounds are used in an equimolar amount for certain applications

[0025] The amount of the compounds of the invention in the composition will often be determined by the physican depending on the dosage required.

[0026] The composition or combination product of the invention is proposed primarily for use in the treatment or prevention of proliferative disorders such as cancer.

[0027] By treating or treatment is meant at least one of:
  1. (i). inhibiting the disease i.e. arresting, reducing or delaying the development of the disease or a relapse thereof or at least one clinical or subclinical symptom thereof, or
  2. (ii). relieving or attenuating one or more of the clinical or subclinical symptoms of the disease.


[0028] By prevention is meant (i) preventing or delaying the appearance of clinical symptoms of the disease developing in a mammal.

[0029] The benefit to a subject to be treated is either statistically significant or at least perceptible to the patient or to the physician. In general a skilled man can appreciate when "treatment" occurs. It is particularly preferred if the composition or combination product of the invention are used therapeutically, i.e. to treat a condition which has manifested rather than prophylactically. It may be that the composition or combination product of the invention is more effective when used therapeutically than prophylactically.

[0030] The composition or combination product of the invention can be used on any animal subject, in particular a mammal and more particularly to a human or an animal serving as a model for a disease (e.g., mouse, monkey, etc.).

[0031] In order to treat a disease an effective amount of the active composition or combination product needs to be administered to a patient. A "therapeutically effective amount" means the amount of a composition or combination product that, when administered to an animal for treating a state, disorder or condition, is sufficient to effect such treatment. The "therapeutically effective amount" will vary depending on the composition or combination product, the disease and its severity and the age, weight, physical condition and responsiveness of the subject to be treated and will be ultimately at the discretion of the attendant doctor.

[0032] It may be that to treat cancer according to the invention that the composition or combination product of the invention has to be readministered at certain intervals. Suitable dosage regimes can be prescribed by a physician.

[0033] The composition or combination product of the invention typically comprises the active components in admixture with at least one pharmaceutically acceptable carrier selected with regard to the intended route of administration and standard pharmaceutical practice.

[0034] The term "carrier" refers to a diluent, excipient, and/or vehicle with which an active compound is administered. The pharmaceutical compositions of the invention may contain combinations of more than one carrier. Such pharmaceutical carriers are well known in the art.. The pharmaceutical compositions may also comprise any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), and/or solubilizing agent(s) and so on. The compositions can also contain other active components, e.g. other drugs for the treatment of cancer.

[0035] It will be appreciated that pharmaceutical composition or combination products for use in accordance with the present invention may be in the form of oral, parenteral, transdermal, sublingual, topical, implant, nasal, or enterally administered (or other mucosally administered) suspensions, capsules or tablets, which may be formulated in conventional manner using one or more pharmaceutically acceptable carriers or excipients. The compositions of the invention could also be formulated as nanoparticle formulations.

[0036] However, for the treatment of cancer, the composition or combination product of the invention will preferably be administered orally or by parenteral or intravenous administration, such as injection. The composition or combination product may therefore be provided in the form of an tablet or solution for injection.

[0037] The pharmaceutical composition or combination product of the invention may contain from 0.01 to 99% weight - per volume of the active material. The therapeutic doses will generally be between about 10 and 2000 mg/day and preferably between about 30 and 1500 mg/day. Other ranges may be used, including, for example, 50-500 mg/day, 50-300 mg/day, 100-200 mg/day.

[0038] Administration may be once a day, twice a day, or more often, and may be decreased during a maintenance phase of the disease or disorder, e.g. once every second or third day instead of every day or twice a day. The dose and the administration frequency will depend on the clinical signs, which confirm maintenance of the remission phase, with the reduction or absence of at least one or more preferably more than one clinical signs of the acute phase known to the person skilled in the art.

[0039] It is within the scope of the present invention to administer the combination products described herein to a subject that has been exposed to, is being exposed to, or will be exposed to one or more anti-proliferative compounds and particularly those known to be used in many anti-cancer therapies. Non-limiting examples include aromatase inhibitors, anti-estrogens, topoisomerase I or II inhibitors microtubule active compounds, alkylating compounds, histone deacetylase inhibitors, and cyclooxygenase inhibitors such as those disclosed in WO2006/122806 and references cited therein Choice of whether to combine a combination product of the invention with one or more of the aforementioned anti-cancer therapies will be guided by recognized parameters known to those of skill in the field, including the particular type of cancer being treated, the age and health of the subject, etc.

[0040] The invention is described further below with reference to the following non-limiting examples and figures.

Description of Figures:



[0041] 

Figure 1 shows co-treatment with cPLA2α inhibitor Compound B and BEZ235 shows synergistic effects on breast cancer cell viability compared to each inhibitor alone. Average and standard deviation of 4 experiments performed in 8 wells.


Examples



[0042] The following compounds were used in the Experiments:

X= CF3 = Compound B


Methods



[0043] Cell Culture. The MDA-MB-468 cell line was from ATCC. This cell line was established from a pleural effusion of patient with metastatic breast adenocarcinoma. The cells were maintained in RPMI medium supplemented with 10% (v/v) FBS, 0.3 mg/mL L-glutamine, and 0.1 mg/mL gentamicin at 37°C in 5% CO2. Sub-culture using trypsin-EDTA was performed every 3-4 days with a split ratio of 1:3- 1:6 to ensure actively proliferating cells.

[0044] Resazurin Viability Assay. Cells were seeded in fully supplemented medium at a density of 7 000 cells per well in 96 well plates. After 24 hrs of cultivation, when the cells were -60% confluent, the medium was replaced with serum free medium to ensure synchronization of the cells and to increase cell sensitivity to treatment. Following 16 hrs of serum starvation, the medium was replaced with fresh serum free medium with or without Compound B, (Avexxin, Norway), and NVP-BEZ235 (Cayman Chemicals, US) or solvent (DMSO, Sigma Aldrich, US). The cells were observed under the microscope to evaluate possible morphology changes and signs of stress before the addition of resazurin according to the manufacturers instructions (RnD Systems, UK). Resazurin was metabolized for 2 hrs (37°C, 5% CO2) before fluorescence was read at 544 nm excitation and 590 nm emission wavelengths (BioTek Synergy HT).

Results



[0045] Co-treatment with the cPLA2α inhibitor Compound B and the PI3K/mTOR inhibitor NVP-BEZ235 shows synergistic effects on breast cancer cell viability compared to each inhibitor alone. Initial experiments were performed to determine the effects of each inhibitor alone. Both Compound B and BEZ235 were toxic to the cells at 25-100µM, whereas at doses 1-5 µM, little or no signs of cellular stress of cytotoxicity were observed (results not shown). On this basis, combination treatment experiments were designed in which sub-toxic doses of the inhibitors were combined. Following 24 hrs of treatment, 5µM BEZ235 and Compound B modestly reduced viability by ∼30% and 20%, respectively. However, when the two inhibitors at 5 µM were combined, a 70% reduction of viability was found, indicating a synergistic and beneficial effect on cancer cell proliferation (Fig. 1). Statistically, our results show:

p<0.005 vs. Ctrl and # p<0.0005 vs. single treatment.


Claims

1. A combination product comprising:

(A) a compound of formula (I):

X= CF3 = Compound A or

X= CF3 = Compound B or a salt thereof; and

(B) a compound of formula (X)

or a pharmaceutically acceptable salt thereof.


 
2. A pharmaceutical composition comprising:

(A) a compound of formula (I):

X= CF3 = Compound A or

X= CF3 = Compound B or a salt thereof; and

(B) a compound of formula (X)

or a pharmaceutically acceptable salt thereof.


 
3. A combination product or pharmaceutical composition as claimed in claim 1 or 2 wherein the pharmaceutically acceptable salt of compound (X) is the 4-toluensulfonic acid salt thereof.
 
4. A pharmaceutical composition for simultaneous, sequential or separate use comprising a kit comprising a first composition comprising a compound (I)

X= CF3 = Compound A or

X= CF3 = Compound B or a salt thereof; and a pharmaceutically-acceptable diluent or carrier; and
a second composition comprising a compound (X)

or a pharmaceutically acceptable salt thereof and a pharmaceutically-acceptable diluent or carrier.
 
5. A pharmaceutical composition or combination product as claimed in claim 1 to 4 for use in the treatment or prevention of a proliferative disorder.
 
6. A pharmaceutical composition or combination product as claimed in claim 5 wherein said proliferative disorder is cancer.
 
7. A pharmaceutical composition or combination product as claimed in claim 6 wherein said proliferative disorder is breast carcinoma.
 
8. A pharmaceutical composition or combination product for use as claimed in claim 5 to 7 comprising administering to a patient an effective amount of a compound of formula (I) and simultaneously, separately or sequentially administering to said patient a compound of formula (X).
 
9. A pharmaceutical composition or combination product of claim 1 to 4 wherein the product is a fixed combination or non-fixed combination.
 
10. A pharmaceutical composition or combination product for use according to claim 5 to 7 in combination with one or more anti-proliferative compounds for use in cancer therapy.
 
11. The pharmaceutical composition or combination product for use as claimed in claim 10, wherein the anti-proliferative compound is selected from the group consisting of aromatase inhibitors, antiestrogens, topoisomerase I or II inhibitors, and microtubule active compounds, alkylating compounds, histone deacetylase inhibitors, and cyclooxygenase inhibitors.
 


Ansprüche

1. Kombinationsprodukt, umfassend:

(A) einen Stoff einer Formel (I):

X = CF3 = Stoff A oder

X = CF3 = Stoff B oder ein Salz hiervon; und

(B) einen Stoff einer Formel (X)

oder ein pharmazeutisch akzeptables Salz hiervon.


 
2. Pharmazeutische Zusammensetzung, umfassend:

(A) einen Stoff einer Formel (I):

X = CF3 = Stoff A oder

X = CF3 = Stoff B oder ein Salz hiervon; und

(B) einen Stoff einer Formel (X)

oder ein pharmazeutisch akzeptables Salz hiervon.


 
3. Kombinationsprodukt oder pharmazeutische Zusammensetzung nach Anspruch 1 oder 2, wobei das pharmazeutisch akzeptable Salz des Stoffes (X) das 4-Toluolsulfonsäure-Salz hiervon ist.
 
4. Pharmazeutische Zusammensetzung zur simultanen, sequenziellen oder separaten Verwendung, umfassend einen Satz, umfassend eine erste Zusammensetzung, umfassend einen Stoff (I)

X = CF3 = Stoff A
oder

X = CF3 = Stoff B
oder ein Salz hiervon; und einen pharmazeutisch akzeptablen Verdünner oder Träger; und
eine zweite Zusammensetzung, umfassend einen Stoff (X)

oder ein pharmazeutisch akzeptables Salz hiervon und einen pharmazeutisch akzeptablen Verdünner oder Träger.
 
5. Pharmazeutische Zusammensetzung oder Kombinationsprodukt nach Anspruch 1 bis 4 zur Verwendung in der Behandlung oder Verhinderung einer Proliferationsstörung.
 
6. Pharmazeutische Zusammensetzung oder Kombinationsprodukt nach Anspruch 5, wobei die Proliferationsstörung Krebs ist.
 
7. Pharmazeutische Zusammensetzung oder Kombinationsprodukt nach Anspruch 6, wobei die Proliferationsstörung ein Brustkarzinom ist.
 
8. Pharmazeutische Zusammensetzung oder Kombinationsprodukt zur Verwendung nach Anspruch 5 bis 7, umfassend ein Verabreichen einer wirksamen Menge eines Stoffes der Formel (I) an einen Patienten und simultan, separat oder sequenziell ein Verabreichen eines Stoffes der Formel (X) an den Patienten.
 
9. Pharmazeutische Zusammensetzung oder Kombinationsprodukt nach Anspruch 1 bis 4, wobei das Produkt eine feststehende Kombination oder nicht feststehende Kombination ist.
 
10. Pharmazeutische Zusammensetzung oder Kombinationsprodukt zur Verwendung nach Anspruch 5 bis 7 in Kombination mit einem oder mehreren Anti-Proliferationsstoffen zur Verwendung in der Krebstherapie.
 
11. Pharmazeutische Zusammensetzung oder Kombinationsprodukt zur Verwendung nach Anspruch 10, wobei der Anti-Proliferationsstoff aus der Gruppe ausgewählt ist, die aus Aromatase-Inhibitoren, Antiestrogenen, Topoisomerase-I- oder -II-Inhibitoren und Mikrotubulus-aktiven Stoffen, alkylierenden Stoffen, Histon-Deacetylase-Inhibitoren und Cyclooxygenase-Inhibitoren besteht.
 


Revendications

1. Produit de combinaison comprenant :

(A) un composé de formule (I) :

X = CF3 = composé A ou

X = CF3 = composé B ou un sel de ceux-ci ; et

(B) un composé de formule (X)

ou un sel pharmaceutiquement acceptable de celui-ci.


 
2. Composition pharmaceutique comprenant :

(A) un composé de formule (I) :

X = CF3 = composé A ou

X = CF3 = composé B

(B) un composé de formule (X)

ou un sel pharmaceutiquement acceptable de celui-ci.


 
3. Produit de combinaison ou composition pharmaceutique selon la revendication 1 ou 2 dans lequel/laquelle le sel pharmaceutiquement acceptable du composé (X) est le sel d'acide 4-toluène-sulfonique de celui-ci.
 
4. Composition pharmaceutique pour une utilisation simultanée, séquentielle ou séparée comprenant un kit comprenant une première composition comprenant un composé (I)

X = CF3 = composé A ou

X = CF3 = composé B
ou un sel de ceux-ci, et un diluant ou véhicule pharmaceutiquement acceptable ; et une seconde composition comprenant un composé (X)

ou un sel de celui-ci pharmaceutiquement acceptable et un diluant ou véhicule pharmaceutiquement acceptable.
 
5. Composition pharmaceutique ou produit de combinaison selon l'une quelconque des revendications 1 à 4 pour une utilisation dans le traitement ou la prévention d'un trouble prolifératif.
 
6. Composition pharmaceutique ou produit de combinaison selon la revendication 5 dans laquelle/lequel ledit trouble prolifératif est un cancer.
 
7. Composition pharmaceutique ou produit de combinaison selon la revendication 6 dans laquelle/lequel ledit trouble prolifératif est un carcinome mammaire.
 
8. Composition pharmaceutique ou produit de combinaison pour une utilisation selon les revendications 5 à 7 comprenant l'administration à un patient d'une quantité efficace d'un composé de formule (I) et simultanément, séparément ou séquentiellement l'administration audit patient d'un composé de formule (X).
 
9. Composition pharmaceutique ou produit de combinaison selon les revendications 1 à 4 dans laquelle/lequel le produit est une combinaison fixe ou une combinaison non fixe.
 
10. Composition pharmaceutique ou produit de combinaison pour une utilisation selon les revendications 5 à 7 en combinaison avec un ou plusieurs agents antiprolifératifs pour une utilisation dans une thérapie du cancer.
 
11. Composition pharmaceutique ou produit de combinaison pour une utilisation selon la revendication 10, dans laquelle/lequel ledit composé antiprolifératif est sélectionné dans le groupe consistant en inhibiteurs de l'aromatase, anti-oestrogènes, inhibiteurs de la topo-isomérase I ou II, et en composés actifs de microtubules, composés alkylants, inhibiteurs de l'histone désacétylase, et inhibiteurs de la cyclo-oxygénase.
 




Drawing








Cited references

REFERENCES CITED IN THE DESCRIPTION



This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description




Non-patent literature cited in the description